| Market Capitalization (Millions $) |
10 |
| Shares
Outstanding (Millions) |
4 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
-6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Cellectar Biosciences Inc. is a clinical-stage biopharmaceutical company that develops targeted drugs for the treatment of cancer. The company primarily focuses on developing novel phospholipid drug conjugates (PDCs), which deliver potent therapeutic agents selectively to cancer cells. Cellectar's PDC platform has the potential to improve the efficacy and safety of current cancer treatments by increasing tumor targeting while reducing damage to healthy cells.
Cellectar's lead product candidate, CLR 131, is being evaluated in multiple Phase 2 clinical trials for various types of cancer, including multiple myeloma, lymphoma, and pediatric solid tumors. CLR 131 targets cancer cells by binding to specific receptors on their surface and delivers a radioactive isotope directly to the tumor, resulting in targeted killing of cancer cells.
In addition to CLR 131, Cellectar has a robust pipeline of other PDC candidates in preclinical development, targeting different types of cancer. The company continues to invest in research and development to expand its product portfolio and explore the potential applications of its innovative technology.
Overall, Cellectar Biosciences Inc. is dedicated to developing targeted therapies that can significantly improve the outcomes and quality of life for cancer patients.
Company Address: 100 Campus Drive Florham Park 7932 NJ
Company Phone Number: 441-8120 Stock Exchange / Ticker: NASDAQ CLRB
|
